

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE RESIGNATION OF NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of the Company dated 30 December 2022 (the “**Announcement**”) in relation to, among others, the resignation of a non-executive Director. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

In addition to the information contained in the Announcement, the Board hereby provides supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.

Save as disclosed above, all other information and contents set out in the Announcement remain unchanged.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Hong Kong, 3 January 2023

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi, Mr. Ng, Joo Yeow Gerry and Dr. Zhang Dan as independent non-executive Directors.